Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XENON ILD: 129Xe MRI in Progressive Fibrosis ILD
NCT05241275Phase 2Active, not recruiting
- Sponsor
- Duke University
- Start
- Jul 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hyperpolarized xenon gas in pulmonary fibrosis (PF) and interstitial lung disease (ILD), sponsored by Duke University. Primary endpoint: Change in 129Xe MRI barrier uptake at 3 months. Started Jul 2022; status: active, not recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05241275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241275.